换用等效吸入剂可节省费用且不影响健康结局
BACKGROUND: Switching inhalers to cheaper equivalent products is often advocated as a necessary cost saving measure, yet the impact on patient's health and healthcare utilisation has not been measured.…
要点
- 换用等效吸入剂与哮喘和慢阻肺急性加重减少相关,未见健康或医疗利用受损。
- 换药后用药依从性显著提高(中位MPR由54%升至62%)。
核心结论
- 在哮喘或慢阻肺患者中换用等效吸入剂看似安全,未对患者健康或医疗利用产生负面影响。
主要发现
- 品牌换仿制药与急性加重减少相关(IRR=0.75,95%CI 0.64至0.88),其他换药类型亦相关(IRR=0.79,95%CI 0.71至0.88)。
- 就诊率(IRR=1.00,95%CI 0.99至1.01)、呼吸事件(IRR=0.96,95%CI 0.95至0.97)和不良药物事件(IRR=1.05,95%CI 0.96至1.15)无显著变化。
- 换药后依从性显著提高(中位MPR:换药前54%,换药后62%;p<0.001)。
关键数值与推荐
- 哮喘与慢阻肺规律吸入剂使用者中分别有2%和6%经历换药。
临床怎么用
- 对哮喘或慢阻肺规律吸入剂使用者,可考虑换用等效吸入剂以节省费用,同时监测急性加重与依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Switching inhalers to cheaper equivalent products is often advocated as a necessary cost saving measure, yet the impact on patient's health and healthcare utilisation has not been measured. METHODS: We identified asthma and chronic obstructive pulmonary disease (COPD) patients from UK primary care electronic healthcare records between 2000 and 2016. A self-controlled case series was used to estimate incidence rate ratios (IRR); comparing outcome rates during the risk period, 3 months after the exposure (financially motivated switch), and control periods (preswitch and postrisk period). Four outcomes were assessed: disease exacerbation, general practitioner consultation, non-specific respiratory events and adverse-medication events. Medication possession ratio (MPR) was calculated to assess adherence. 2017 National Health Service indicative prices were used to estimate cost differences per equivalent dose. RESULTS: We identified a cohort of 569 901 asthma and 171 231 COPD regular inhaler users, 2% and 6% had been switched, respectively. Inhaler switches between a brand-to-generic inhaler, and all other switches (brand-to-brand, generic-to-generic, generic-to-brand), were associated with reduced exacerbations (brand-to-generic: IRR=0.75, 95% CI 0.64 to 0.88; all other: IRR=0.79, 95% CI 0.71 to 0.88). Gender, age, therapeutic class, inhaler device and inhaler-technique checks did not significantly modify this association (p<0.05). The rate of consultations, respiratory-events and adverse-medication events did not change significantly (consultations: IRR=1.00, 95% CI 0.99 to 1.01; respiratory-events: IRR=0.96, 95% CI 0.95 to 0.97; adverse-medication-events: IRR=1.05, 95% CI 0.96 to 1.15). Adherence significantly increased post-switch (median MPR: pre-switch=54%, post-switch=62%; p<0.001). Switching patients, in the cohort of regular inhaler users, to the cheapest equivalent inhaler, could have saved around £6 million annually. CONCLUSION: Switching to an equivalent inhaler in patients with asthma or COPD appeared safe and did not negatively affect patient's health or healthcare utilisation.
引用
- Bloom CI, Douglas I, Olney J, et al. Cost saving of switching to equivalent inhalers and its effect on health outcomes. Thorax. 2019. PMID: 31383774. doi:10.1136/thoraxjnl-2018-212957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。